尤瑞克林注射液对内囊预警综合征后脑梗死患者疗效及血清基质金属蛋白酶9的影响

Effect of Kallikrein on Serum Matrix Metalloproteinase-9 (MMP-9) and its Clinical Efficacy in Patients with Capsular Warning Syndrome

目的研究尤瑞克林注射液对内囊预擎综合征后进展为脑梗死患者的临床疗效和血清基质金属蛋白酶-9 (matrix metalioproteinase-9,MMP-9)水平的影响。方法将内囊预警综合征进展为脑梗死的患者31例随机分为对照组和治疗组,治疗组16例,对照组15例,治疗组在常规治疗基础上加用尤瑞克林注射液,连续用药14 d。评价两组治疗前后血清MMP-9水平,以及入院和发病3个月后两组美国国立卫生研究院卒中量表(National Institutes of Health StrokeScale,NIHSS)及Barthel指数(Barthel index,BI)的变化。结果两组3个月后神经功能缺失程度评分与本组入院时相比,NIHSS分值下降,BI分值增加,差异有统计学意义(P均<0.01)。治疗组治疗后3个月NIHSS评较对照组低,引评分较高(P<0.01)。治疗后两组血清MMP-9水平均较本组治疗前下降(P均<0.01),治疗后治疗组较对照组的血清MMP-9水平更低(P<0.01)。结论尤瑞克林注射液可促进内囊预警综合征进展为脑梗死患者神经功能的恢复,降低血清MMP-9水平。

To investigate the effects of Kallikrein on serum matrix metalloproteinase-9（MMP-9） and its clinical efficacy in patients with stroke coming from capsular warning syndrome. Methods Thirty-one patients with stroke coming from capsular warning syndrome were randomly divided into control group（n=15） and treatment group（n=16）. Each group was consistently given 14 days basical treatment, treatment group was given Kallikrein else. The serum levels of MMP- 9 were detected before and after treatment. All patients＇ never function was assessed by National Institutes of Health Stroke Scale（NIHSS） and Barthel Index（BI） at admission and at 3 months after admission. Results Compared with that at admission, NIHSS decreased and BI increased at 3 months, there was statistical deference in two groups（each P 〈 0.001）, and treatment group has lower NIHSS and higher BI （P〈 0.001）. After treatment, obvious decrease of serum MMP-9 concentration was seen in both groups comparing with non-treatment（each P 〈 0.01）, and treatment group was lower than control group（P〈 0.01）. Conclusion Kallikrein can improve functional neurological recovery and reduce the serum level of MMP-9 in patients with stroke coming from capsular warning syndrome.